LKFT Lakefront Biotherapeutics NV IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY303.5%
TTM net income YoY333.1%
TTM EPS YoY334.8%
Revenue 3-yr CAGR66.4%
Net income 3-yr CAGR—
Margins
Gross margin97.3%
Operating margin26.5%
Net margin28.9%
FCF margin-24.4%
EBITDA margin—
Returns
ROE10.5%
ROA8.5%
ROIC (approx.)9.9%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets5.0%
Debt / equity0.00x
Current ratio20.15x
Interest coverage285.34x
Cash quality & payout
Operating cash flow / net income-0.80x
Accruals ratio15.3%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 1.11B | 275.65M |
| Cost of revenue | 29.74M | 34.86M |
| Gross profit | 1.08B | 240.79M |
| R&D expense | 459.42M | 335.46M |
| SG&A expense | 147.33M | 117.25M |
| Operating income | 295.04M | -188.34M |
| Interest expense | 1.03M | 911,000 |
| Pretax income | 300.87M | -3.08M |
| Income tax | -18.62M | -1.80M |
| Net income | 320.88M | 74.08M |
| EPS (basic) | 4.87 | 1.12 |
| EPS (diluted) | 4.87 | 1.12 |
| Weighted avg. shares (diluted) | 65.90M | 65.90M |
| Balance sheet | ||
| Cash & equivalents | 87.87M | 64.24M |
| Short-term investments | 2.91B | 3.05B |
| Receivables | 20.71M | 47.48M |
| Inventory | 22.49M | 51.19M |
| Current assets | 3.08B | 3.34B |
| PP&E, netmay include right-of-use assets (IFRS) | 71.95M | 105.40M |
| Goodwill | — | 70.01M |
| Intangibles | 848,000 | 164.86M |
| Total assets | 3.41B | 4.14B |
| Current liabilities | 152.86M | 335.08M |
| Total liabilities | 170.65M | 1.24B |
| Shareholders' equity | 3.24B | 2.90B |
| Cash flow statement | ||
| Operating cash flow | -257.46M | -320.03M |
| Capital expenditure | 13.70M | 16.72M |
| Free cash flow | -271.16M | -336.75M |
| Investing cash flow | 288.81M | 220.60M |
| Financing cash flow | -3.27M | -4.92M |
| Stock-based compensation | 24.00M | 19.89M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.